Replies to post #134152 on NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Exwannabe, I totally agree with your post.

SoS concludes the other 2 trials show why NWBO needs to run the DCVax-L trial well past planned endpoint analysis. The argument is it needs the data. Yet the two comp trials were successful at substantially shorter early stops. -- exwannabe

[jammyjames]

Whilst i agree that SOS doesn't know what he's talking about you're bullshitting a bit here ex.

Advanced squamous nsclc has mOS of only several months with docetaxel. You need a much shorter time to hit stat sig with an equivalent effect size in this trial

The advanced met/adv RCC had n=792 with similar mOS to ndGBM. With that n number you also hit stat sig much earlier with an equivalent effect size.

Apples with oranges

I'll get back to your other flawed comment about no alpha left after primary failure tmrw...hate writing on a tablet or phone!